IPV
Resource Event Discussion
View all
No content found
View all

Intermittent inadequate vaccine supply – one of the causes of negative drop out

Dear viewers Short supply of vaciines requiring multiple doses is one of the causes of accentuating negeative dropout rate, making the indicator invalid for programme review. India

Polio,
IPV,
Wastage,
  1. Last updated was 5 years ago

Lesson learnt from PHC Kollamogru: Year April 2016 to March 2017.

Dear viewers Sharing the following with the viewers who are the true Polio Eradicators / planners / managers / authorized implementers & policy makers of the programme Good intentio

Polio,
IPV,
Distribution system,
Coverage monitoring,
  1. Last updated was 5 years ago

Positive thinking: Failure as a precursor for success

Dear members and viewers of technet viewers We wish to share the following and hope to achieve something by clearing the backlog of infants accumulated for receving 1st and 2nd doses of fractional

TB,
Coverage monitoring,
IPV,
  1. Last updated was 6 years ago

My first experience at vaccinating a child...as part of a Vaccination Outreach Programme in Rural India

Hello everyone! This is my very first post here. I am a 3rd year Student of Medicine(M.B.B.S) studying at

Measles,
IPV,
Pentavalent,
OPV,
BCG,
  1. Last updated was 6 years ago

First experiences from the ‘FIRST’ IPV vials

Dear viewers Out of inquisitiveness, we studied the usage of the First IPV vial of 5 facilities and got many things to learn from the service providers of 3 attached planning units, one Fir

Polio,
Intradermal,
IPV,
  1. Last updated was 6 years ago

BCG & IPV on "Wheals"

Dear viewers We wish to share our very short study finding with the TechNet viewers for further input and mutual sharing of experiences for the global benefit of closing the imuunization ga

Intradermal,
IPV,
BCG,
  1. Last updated was 6 years ago

Close the immunization gap: Intradermal administration of vaccines

For realizing the above, identifying maximum causes of gap and operating good practices for mitigation is essential to meet the global vaccination targets by 2020. We made video recording a

Injection safety,
IPV,
Intradermal,
  1. Last updated was 6 years ago

Global switch in oral polio vaccines: live tracking of progress

From 17 April to 1 May, the globally synchronised switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) is taking place in 155 countries and territories. This will b

Poliomyelitis,
Polio,
OPV,
IPV,
  1. Last updated was 6 years ago

Global polio vaccine switch confirmed for April 2016

The Strategic Advisory Group of Experts on immunization (SAGE) convened by WHO on 20 October 2015 has confirmed that the globally coordinated withdrawal of the type 2 component in the oral poliovir

Poliomyelitis,
Polio,
OPV,
Vaccine management,
IPV,
  1. Last updated was 7 years ago
View all in Knowledge Hub

March 2019 VIEW-hub Report: Global Vaccine Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

December 2018 VIEW-hub Report on Global Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

September 2018 VIEW-hub Report: Global Vaccine Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

June 2018 VIEW-hub Report on Global Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

Report from the Seventeenth Meeting Global Commission for the Certification of the Eradication of Poliomyelitis

The Global Commission for the Certification of Poliomyelitis Eradication (GCCPE/GCC) met in February 2018. It noted that although no WPV paralytic cases had been reported in Pakistan since November 2017 and fewer cases were being reported from...

The path towards polio eradication over 40 years of the Expanded Program on Immunization in the Americas

This article synthesizes the important lessons learned from polio eradication in the Region of the Americas, including initial and more recent challenges and best practices, as well as particular factors surrounding attainment of this ambitious...

Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the NanopatchTM Microprojection Array

The worldwide switch to inactivated polio vaccines (IPV) is a key component of the overall strategy to achieve and maintain global polio eradication. To this end, new IPV vaccine delivery systems may enhance patient convenience and compliance. In...

December 2017 VIEW-hub Report on Global Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses

To secure a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be replaced with inactivated poliovirus vaccines (IPV). However, current IPV delivery is less suitable for campaign use than OPV, and more...

Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio

essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global switch from...

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes

Background: Comparing model expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV2) cessation can inform risk management for the expected cessation of OPV containing serotypes 1 and 3 (OPV13). Methods: We...

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission

Background: Recent detections of circulating serotype 2 vaccine-derived poliovirus in northern Nigeria (Borno and Sokoto states) and Pakistan (Balochistan Province) and serotype 1 wild poliovirus in Pakistan, Afghanistan, and Nigeria (Borno)...

Monitoring and Validation of the Global Replacement of tOPV with bOPV, April–May 2016

The phased withdrawal of oral polio vaccine (OPV) associated with the Polio Eradication and Endgame Strategic Plan 2013-2018 began with the synchronized global replacement of trivalent OPV (tOPV) with bivalent OPV (bOPV) during April - May 2016, a...

Administering Multiple Injectable Vaccines During a Single Visit—Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally

Background: In 2013, the World Health Organization’s (WHO’s) Strategic Advisory Group of Experts (SAGE) recommended that all 126 countries using only oral polio vaccine (OPV) introduce at least 1 dose of inactivated polio vaccine (IPV) into...

Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania

Background: Albania introduced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasing the maximum recommended number of injectable vaccines given in a single visit from 2 to 3. Methods: Health-care providers and...

Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines

Oral polio vaccine (OPV) and Inactivated Polio Vaccine (IPV) have distinct advantages and limitations. IPV does not provide mucosal immunity and introduction of IPV to mitigate consequences of circulating vaccine-derived polio virus from OPV has...

Succeeding in New Vaccine Introduction: Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Cameroon, Kenya, and Nigeria

Introducing a new vaccine is a large-scale endeavor that can face many challenges, resulting in introduction delays and inefficiencies. The development of national task teams and tools, such as prelaunch trackers, for the introduction of new...

Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April–November 2015

Background: Kano State, Nigeria, introduced inactivated polio vaccine (IPV) into its routine immunization (RI) schedule in March 2015 and was the pilot site for an RI data module for the National Health Management Information System (NHMIS). We...

Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh

Background: We assessed programmatic adaptations and infants\' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunization schedule in Bangladesh. Methods: Using convenience and probability sampling, we...

Cold-Chain Adaptability During Introduction of Inactivated Polio Vaccine in Bangladesh, 2015

Background: Introduction of inactivated polio vaccine creates challenges in maintaining the cold chain for vaccine storage and distribution. Methods. We evaluated the cold chain in 23 health facilities and 36 outreach vaccination sessions in 8...

The Role of National Immunization Technical Advisory Groups (NITAGs) in the Introduction of Inactivated Polio Vaccine: Experience of the Indonesia and Uganda NITAGs

National Immunization Technical Advisory Groups (NITAGs) are established by national authorities to provide them with independent, bias-free, objective, and evidence-based advice on vaccines and immunization challenges. As of December 2015, 125...

Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region

The World Health Organization (WHO) Western Pacific Region (WPR) has maintained its polio-free status since 2000. The emergence of vaccine-derived polioviruses (VDPVs), however, remains a risk, as oral polio vaccine (OPV) is still used in many of...

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region

This analysis describes an innovative and successful approach to risk identification and mitigation in relation to the switch from trivalent to bivalent oral polio vaccine (OPV) in the 11 countries of the World Health Organization’s (WHO’s)...

Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region

The Global Polio Eradication Initiative has reduced the global incidence of polio by 99% and the number of countries with endemic polio from 125 to 3 countries. The Polio Eradication and Endgame Strategic Plan 2013–2018 (Endgame Plan) was...

Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas

The synchronized introduction of the inactivated polio vaccine (IPV) and the switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) has constituted an effort without precedents, and with astonishing results. Within the...

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region

The Polio Eradication and Endgame Strategic plan outlines the phased removal of oral polio vaccines (OPVs), starting with type 2 poliovirus–containing vaccine and introduction of inactivated polio vaccine in routine immunization to mitigate...

June 2017 VIEW-hub Report on Global Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

Exceptional financial support for introduction of Inactivated Polio Vaccine in middle-income countries

n May 2012, the World Health Assembly declared the completion of poliovirus eradication a programmatic emergency for global public health and called for a comprehensive polio endgame strategy. The Polio Eradication and Endgame Strategic Plan...

Regulatory aspects of Sabin Type 2 withdrawal from trivalent Oral Poliovirus Vaccine: Process and lessons learned

Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries required regulatory approval for use of inactivated poliovirus vaccine and bivalent OPV in routine immunization. Worldwide, a variety of mechanisms were used by member states,...

Managing the planned cessation of a global supply market: Lessons learned from the global cessation of the trivalent Oral Poliovirus Vaccine market

The Polio Eradication and Endgame Strategic Plan 2013-2018 calls for the phased withdrawal of OPV, beginning with the globally synchronized cessation of tOPV by mid 2016. From a global vaccine supply management perspective, the strategy provided two...

A supply and demand management perspective on the accelerated global introductions of Inactivated Poliovirus Vaccine in a constrained supply market

A total of 105 countries have introduced IPV as of September 2016 of which 85 have procured the vaccine through UNICEF. The Global Eradication and Endgame Strategic Plan 2013-2018 called for the rapid introduction of at least one dose of IPV into...

Communications, immunization, and polio vaccines: Lessons from a global perspective on generating political will, informing decision-making and planning, and engaging local support

The requirements under objective 2 of the Polio Eradication and Endgame Strategic Plan 2013–2018—to introduce at least 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), starting with the type 2...

Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the polio endgame

The Immunization Systems Management Group (IMG) was established as a time-limited entity, responsible for the management and coordination of Objective 2 of the Polio Eradication and Endgame Strategic Plan. This objective called for the introduction...

Polio endgame: Lessons learned from the Immunization Systems Management Group

The Immunization Systems Management Group (IMG) was established to coordinate and oversee objective 2 of the Polio Eradication and Endgame Strategic Plan 2013–2018, namely, (1) introduction of ≥1 dose of inactivated poliovirus vaccine in all 126...

Progress toward containment of poliovirus Type 2 — worldwide, 2017

The Global Polio Eradication Initiative (GPEI) continues to make progress toward the eradication target. Only one of the three serotypes, wild poliovirus (WPV) type 1 (WPV1), is still circulating, and the numbers of cases and countries with endemic...

Maximising the impact of inactivated polio vaccines

With the globally coordinated switch from the trivalent oral polio vaccine (OPV) to the bivalent OPV in April, 2016, the international public health community entered a new chapter in the endgame of polio. Although OPV has served as the cornerstone...

Effects of polio eradication activities on routine immunization: lessons from the 2013 outbreak response in Somali region of Ethiopia

Introduction: Ethiopia experienced several WPV importations with a total of 10 WPV1 cases confirmed during the 2013 outbreak alone before it is closed in 2015. We evaluated supplemental immunization activities (SIAs), including lessons learned for...

Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America

Background: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally...

VIEW-hub Report

The VIEW-hub report: Global Vaccine Introduction and Implementation, is also now available. A summary companion to IVAC’s interactive VIEW-hub platform, the VIEW-hub report displays data and figures on the introduction status of PCV, RVV, and...

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age

There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first...

Guidance for assessment of poliovirus vaccination status and vaccination of children who have received poliovirus vaccine outside the United States

In 1988, the World Health Assembly resolved to eradicate poliomyelitis (polio). Since then, wild poliovirus (WPV) cases have declined by >99.9%, from an estimated 350,000 cases of polio each year to 74 cases in two countries in 2015 (1). This...

Wild and vaccine-derived poliovirus circulation, and implications for polio eradication

Polio cases due to wild virus are reported by only three countries in the world. Poliovirus type 2 has been globally eradicated and the last detection of poliovirus type 3 dates to November 2012. Poliovirus type 1 remains the only circulating wild...

National Emergency Action Plan for Polio Eradication 2016-2017 (Pakistan)

In this National Emergency Action Plan (NEAP) for 2016 - 2017, the main objective is to stop transmission in the core reservoirs and maintain or increase population immunity against polio in the rest of the country. To achieve this, the programme...

Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants

Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines...

Polio endgame, information gaps related to vaccines and immunity

Evidence generated through research studies has guided programmatic actions and fine-tuned strategies for the Global Polio Eradication Initiative (GPEI). However, many gaps still persist in the understanding of a risk-free implementation of the...

India's preparedness for introduction of IPV and switch from tOPV to bOPV

Global Polio Eradication and Endgame Strategic Plan 2013-18 calls for the ultimate withdrawal of oral polio vaccines (OPV) from all immunization programs across the world. The phased globally synchronized withdrawal would begin with type 2 serotype...

September 2016 VIEW-hub Report on Global Introduction and Implementation

The following report displays data and figures on the introduction status of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in 73 Gavi countries (currently eligible and graduating...

Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: Spatio-temporal modelling of surveillance data

In August 2015, we estimated vaccine-induced population immunity against serotype-2 poliomyelitis for 1 January 2004–30 June 2015 and produced forecasts for April 2016 by district in Nigeria and Pakistan. Population immunity was estimated from the...

The need and potential of Inactivated Poliovirus Vaccine

As the polio endgame progresses, the world will increasingly rely on inactivated polio vaccine (IPV) for protection against polio (wild and vaccine-related) and for risk mitigation during the phased removal of oral polio vaccine (OPV). IPV has...

Effect of booster doses of poliovirus vaccine in previously vaccinated children, Clinical Trial Results 2013

BACKGROUND: Considering the current polio situation Pakistan needs vaccine combinations to reach maximum population level immunity. The trial assessed whether inactivated poliovirus vaccine (IPV) can be used to rapidly boost immunity among children...

View all
No content found
View all
No content found